Development of next-generation neuromodulatory therapeutics by theta burst stimulation for alcohol use disorder and elucidation of its therapeutic mechanism - Next-generation neuromodulatory therapeutics by TBS for alcohol use disorder

akajima Shinichiro0 个研究点目标入组 30 人开始时间: 2024年2月22日最近更新: 2024年5月27日

试验速览

暂无简介。

•1.Outpatients who meet the criteria for alcohol use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
•2.Outpatients who provided informed consent
•3.Men and women between the ages of 20 and 64 at the time of obtaining written informed consent
•4.Outpatients who are able to visit Keio University Hospital according to our research schedule
•5.Outpatients whose mental states are stable enough to take examinations that may take approximately four hours

•1. Patients who have organic brain diseases (e.g., intracranial organic lesions of moderate or higher grade, or neurodegenerative diseases)
•2. Patients with a history of seizures or epilepsy
•3. Patients with serious or unstable physical illnesses
•4. Receiving electroconvulsive therapy within 6 months prior to enrollment
•5. Being pregnant, breastfeeding, or hoping to become pregnant
•6. Having a metallic substance in the body or having a peacemaker
•7. Patients with claustrophobia
•8. Having tattoos (including tattoos and art make-up) that are larger than one point in the head or neck
•9. The size of the head, neck and body are not suitable for MRI scanners
•10. Having obvious hearing loss
•11. Those deemed unsuitable as research subjects by the principal investigator

发起方

akajima Shinichiro